Market Runner: What’s Ahead for Ultragenyx Pharmaceutical Inc After Today’s Huge Decline?

Market Runner: What's Ahead for Ultragenyx Pharmaceutical Inc After Today's Huge Decline?

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! About 637,725 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 21.00% since April 27, 2016 and is uptrending. It has outperformed by 15.77% the S&P500.
The move comes after 7 months negative chart setup for the $3.28 billion company. It was reported on Nov, 30 by Barchart.com. We have $70.76 PT which if reached, will make NASDAQ:RARE worth $295.20 million less.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on February, 23. They expect $-1.74 EPS, down 22.54% or $0.32 from last year’s $-1.42 per share. After $-1.64 actual EPS reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 6.10% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 13 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 92% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 21 analyst reports since July 27, 2015 according to StockzIntelligence Inc. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, June 8 report. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) earned “Buy” rating by Bank of America on Tuesday, June 28. As per Tuesday, September 1, the company rating was initiated by Raymond James. Morgan Stanley downgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Monday, July 27 to “Equal Weight” rating. Citigroup upgraded Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Tuesday, January 12 to “Neutral” rating. As per Tuesday, December 22, the company rating was initiated by Canaccord Genuity. As per Tuesday, December 1, the company rating was initiated by Stifel Nicolaus. SunTrust maintained the shares of RARE in a report on Monday, July 13 with “Buy” rating. H.C. Wainwright initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Tuesday, February 9. H.C. Wainwright has “Buy” rating and $104 price target. Jefferies initiated the stock with “Buy” rating in Friday, October 23 report.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.24, from 0.97 in 2016Q1. The ratio increased, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Rockefeller Svcs accumulated 396,346 shares or 0.39% of the stock. Price T Rowe Assoc Md owns 1.59M shares or 0.02% of their US portfolio. Paradigm Asset Management Company Ltd Company has 1,750 shares for 0% of their US portfolio. Susquehanna Grp Llp holds 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 27,563 shares. Eagle Asset Mngmt holds 342,540 shares or 0.12% of its portfolio. Moreover, Fmr Ltd Liability has 0.04% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 5.85 million shares. Strs Ohio, a Ohio-based fund reported 6,300 shares. Geode Cap Ltd Liability Company holds 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 263,221 shares. Voya Investment Mngmt Ltd Liability Corp holds 0.02% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 148,063 shares. Moreover, One Trading L P has 0% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 6,125 shares. Wellington Gru Limited Liability Partnership has 4.19M shares for 0.05% of their US portfolio. Raymond James Assoc has 4,749 shares for 0% of their US portfolio. Rock Springs Cap Mgmt Limited Partnership has 141,500 shares for 0.51% of their US portfolio. Bluemountain Mgmt Ltd Liability Co has 6,770 shares for 0.01% of their US portfolio. Polar Ltd Liability Partnership last reported 4,917 shares in the company.

Another recent and important Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) news was published by Streetinsider.com which published an article titled: “Ultragenyx Pharma (RARE) Announces Significant Data from UX007 Phase 2 in LC-FAOD” on November 30, 2016.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment